Jim Weiss founded WeissComm Partners as a one-person healthcare communications consultancy in San Francisco in 2001, building it through several name changes, WCG, then W2O Group, then Real Chemistry, into the largest healthcare-focused public relations and marketing firm in the United States.
Who is Jim Weiss?
Jim Weiss is the founder of Real Chemistry, a graduate magna cum laude of Syracuse University's S.I. Newhouse School of Public Communications with a B.S. in journalism and public relations. He was later inducted into the Newhouse Hall of Fame and named to the school's 50Forward list of the program's most accomplished graduates of the last 50 years.
Weiss began his career at biotechnology bellwether Genentech during its formative growth period, then helped establish the global product marketing communications function at pharmaceutical giant Sanofi in Paris, before becoming head of corporate communications and investor relations at Bay Area medical device startup Heartport, a pioneer in minimally invasive cardiac surgery. That client-side sequence across biotech, big pharma, and medical devices, spanning most of the first half of his career, gave Weiss the vantage point of a communications buyer before he ever ran an agency, an experience he has said directly inspired him to build the kind of firm he would have wanted to hire.
Weiss and his wife Audra co-founded the W2O Group Center for Social Commerce at Newhouse in 2012, an industry-academic partnership focused on data analytics, social media strategy, and digital communications, extending Weiss's influence on the field into curriculum and research rather than agency work alone. In 2016, Weiss partnered with Kim Hunter at The LAGRANT Foundation to create the first paid healthcare communications fellowship of its kind, placing multicultural professionals pursuing healthcare communications careers directly inside a W2O office; he continues to sit on the Foundation's board of directors.
How did WeissComm become W2O Group?
Weiss founded WeissComm Partners in 2001 as a solo healthcare-focused consultancy handling investor relations and corporate communications for life sciences and biopharma clients. The firm grew organically through the 2000s, adding analytics, social, and digital capabilities, and by the early 2010s operated as WCG before unifying its brands under the W2O Group name.
Throughout that growth, Weiss built the firm around a bet few competitors were making at the time: hiring engineers and data scientists alongside communicators, years before "data-driven PR" became an industry-wide talking point. In 2019, New Mountain Capital took a majority stake in the firm, capital that funded an aggressive run of roughly 10 acquisitions between 2019 and 2023 across analytics, influencer marketing, and medical-education specialists, transforming W2O Group from a healthcare communications shop into a broader health-innovation platform. On March 10, 2021, the firm rebranded entirely to Real Chemistry, a name meant to capture the combined communications, advertising, digital marketing, data analytics, clinical trial services, and health-economics advisory work the firm now performs under one roof.
Why did Weiss build around healthcare specifically?
Healthcare communications carries structurally different stakes than consumer PR: audiences are fragmented across physicians, patients, payers, regulators, and investors, and a mishandled product launch can affect drug approvals and market capitalization rather than only brand perception. Weiss built the firm to operate inside that complexity, integrating analytics, predictive modeling, influencer infrastructure, and medical education under one roof.
What recognition has Weiss received?
Weiss has appeared on the PRWeek Power List in 2012, 2013, and 2014, was named to the 500 Most Important People in the Global PR Industry in 2015 and 2017, was recognized as a Top 25 Innovator in Communications in 2014 and Innovator of the Year in 2020, and has repeated as a Top 50 Health Influencer across 2016 through 2019. In 2023, the PM360 Trailblazer Awards recognized Weiss with a Lifetime Achievement Award, marking a 36-year career he has summarized publicly with the hashtag "#MakeItHappen." He sits on the board of trustees for the Cancer Research Institute, where he serves on the Marketing Subcommittee, is a trustee of the Commons Project Foundation, and sits on the advisory board of the Healthcare Businesswomen's Association.
What is the firm's current status?
Real Chemistry reported approximately $555 million in 2022 revenue and roughly $560 million in 2025 revenue, operating from 10 locations with more than 2,000 employees and partnerships with 29 of the top 30 global pharmaceutical companies. Weiss serves as Chairman, having transitioned the CEO role to Shankar Narayanan in January 2022, and the firm remains the largest healthcare-focused communications and marketing firm in the United States by most industry measures, still majority-owned by New Mountain Capital.
How does his firm's model compare to other US specialist founders?
Where Weiss built his firm into one of the largest healthcare specialists in the country through acquisitions and data infrastructure, other American specialist founders such as Michael Sitrick's Sitrick And Company took the opposite path, staying deliberately boutique in crisis and litigation communications rather than scaling through acquisition. Both picked a single hard vertical and specialized rather than pursuing multi-sector breadth.
Adjacent EPR frameworks
